Abstract No. 4 ▪ ABSTRACT OF THE YEAR Preliminary Results of the FRONTIER Trial: Safety and Feasibility of Yttrium-90 TheraSphere in Recurrent Glioblastoma
Glioblastoma (GBM) is a highly aggressive brain tumor with poor prognosis, particularly in recurrent cases where treatments are limited. Yttrium-90 (Y90) microsphere therapy, successfully used for hepatic malignancies, offers the potential for targeted radiation in GBM. The FRONTIER trial evaluates the safety and feasibility of TheraSphere GBM Y90-microsphere treatment, in patients with recurrent GBM.
vigna
0
0
Glioblastoma (GBM) is a highly aggressive brain tumor with poor prognosis, particularly in recurrent cases where treatments are limited. Yttrium-90 (Y90) microsphere therapy, successfully used for hepatic malignancies, offers the potential for targeted radiation in GBM. The FRONTIER trial evaluates the safety and feasibility of TheraSphere GBM Y90-microsphere treatment, in patients with recurrent GBM.
